

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.

杭州九源基因生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2566)

INSIDE INFORMATION COMPLETION OF THE H SHARE FULL CIRCULATION

The announcement is made by Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**Inside Information Provisions**”).

References are made to (i) the announcement of the Company dated December 2, 2025 in relation to, among other things, the proposed implementation of the H Share Full Circulation; (ii) the circular of the Company dated December 2, 2025 in relation to, among other things, proposed H Share Full Circulation; (iii) the announcement of the Company dated December 22, 2025 in relation to the poll results of the second extraordinary general meeting of 2025; (iv) the announcement of the Company dated April 2, 2026 in relation to the issuance of the Filing Notice by the CSRC for the H share full circulation application of the Company; and (v) the announcement of the Company dated May 8, 2026 in relation to the grant of listing approval by the Stock Exchange for the implementation of the H Share Full Circulation (collectively, the “**Circular and Announcements**”). Unless otherwise stated, terms used herein shall have the same meanings as those defined in the Circular and Announcements.

COMPLETION OF THE H SHARE FULL CIRCULATION

The Board of the Company is pleased to announce that the conversion of 136,302,015 Unlisted Shares into H Shares had been completed on May 14, 2026, and the listing of the Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on May 15, 2026.

SHAREHOLDING STRUCTURE

The shareholding structure of the Company immediately before and upon the completion of the Conversion and Listing is set out below:

Class of Shares	As of the date of this announcement		Upon completion of the Conversion and Listing	
	Number of share	Approximate percentage of the total number of issued shares of the Company (%)	Number of share	Approximate percentage of the total number of issued shares of the Company (%)
H shares	109,096,785	44.5	245,398,800	100.0
Unlisted shares	136,302,015	55.5	–	–
Total	245,398,800	100.0	245,398,800	100.0

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
 杭州九源基因生物醫藥股份有限公司
FU Hang
Executive Director, Chairman of the Board and General Manager

Hangzhou, the PRC, May 14, 2026

As of the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; and (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀) and Dr. Zhou Demin (周德敏) as independent non-executive directors.